Zealand Pharma AS (ZEAL) DKK1
- Add to watchlist
- This stock can be held in a
Business summary
Zealand Pharma A/S is a Denmark-based biotechnology company. The Company is focused on the discovery, design and development of peptide-based medicines for metabolic and gastrointestinal diseases and other rare disease areas with unmet medical needs. The Company's peptide-based product candidates includes clinical development, registration and, potentially, commercialization. Its pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome, or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for better diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The Company operates in Denmark and the USA and has a portfolio of medicines and product candidates, including collaborations with Boehringer Ingelheim.
Contact details
Important dates
General stock information
- Short code:
- ZEAL
- ISIN:
- DK0060257814
- Market cap:
- 55.97 billion DKK
- Shares in issue:
- 70.95 million
- Sector:
- Biotechnology
- Exchange:
- Copenhagen Stock Exchange
- Country:
- Denmark
- Currency:
- Danish Krone
- Indices:
- OMX Copenhagen 20
Key personnel
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.